Patents by Inventor Norbert Rasenack
Norbert Rasenack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11642315Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.Type: GrantFiled: September 28, 2018Date of Patent: May 9, 2023Assignee: Novartis AGInventors: Elodia Di Renzo, David Hook, Markus Krumme, Steffen Lang, Massimo Moratto, Joerg Ogorka, Jim Parks, Dale Ploeger, Norbert Rasenack, Hendrik Schneider, Stefan Steigmiller, Gordon Stout, Patrick Tritschler, Fabian Weber
-
Publication number: 20220202728Abstract: A formulation for injection moulding of a pharmaceutical carrier comprising 27-85% (w/w) of polyvinyl alcohol, and 10-60% (w/w) of a disintegration aid selected from maize starch, wheat starch, and combinations thereof; and optionally one or more excipients.Type: ApplicationFiled: April 1, 2020Publication date: June 30, 2022Inventors: Florian BECK, Hans de Waard, Sarah Gold, Stefan Hirsch, David Hook, Nikhil Kavimandan, Markus Krumme, Steffen Lang, Detlef MOLL, Siddharthya Mujumdar, Anh-Thu Nguyen-Trung, Joerg Ogorka, Norbert Rasenack, Maxime Thomas-Schrapp, Raphael TOBLER, Patrick Tritschler
-
Publication number: 20220175682Abstract: The present invention relates to methods of preparing pharmaceutical products, involving filling active pharmaceutical ingredient powders into pharmaceutical carriers with a vacuum assisted metering and filling device. The methods disclosed herein can be used in a continuous process, such as in a high-throughput process for producing a pharmaceutical product. The present invention further relates to a particular quality of the neat active pharmaceutical ingredient (API) HDM201, i.e. siremadlin, present as succinic acid co-crystal, which can be used in the methods of preparation of the present invention.Type: ApplicationFiled: April 2, 2020Publication date: June 9, 2022Inventors: Nicole BIERI, Elodia DI RENZO, David HOOK, Jennifer Claire HOOTON, Markus KRUMME, Steffen LANG, Franck MALLET, Massimo MORATTO, Joerg OGORKA, Jim PARKS, Dale W. PLOEGER, Norbert RASENACK, Hendrik SCHNEIDER, Lipa SHAH, Stefan STEIGMILLER, Gordon STOUT, Patrick TRITSCHLER, Fabian WEBER
-
Publication number: 20200315973Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.Type: ApplicationFiled: September 28, 2018Publication date: October 8, 2020Inventors: Elodia Di Renzo, David Hook, Markus Krumme, Steffen Lang, Massimo Moratto, Joerg Ogorka, Jim Parks, Dale Ploeger, Norbert Rasenack, Hendrik Schneider, Stefan Steigmiller, Gordon Stout, Patrick Tritschler, Fabian Weber
-
Publication number: 20200306198Abstract: A formulation for injection molding of a pharmaceutical carrier comprises 43.5-97% (w/w) of one or more polyethylene oxide polymer having a weight average molecular weight of MW 94,000-188,000; and optionally one or more excipients.Type: ApplicationFiled: September 28, 2018Publication date: October 1, 2020Inventors: Florian Beck, Hans de Waard, Sarah Gold, Stefan Hirsch, David Hook, Nikhil Kavimandan, Markus Krumme, Steffen Lang, Detlef Moll, Siddharthya Mujumdar, Anh-Thu Nguyen-Trung, Joerg Ogorka, Norbert Rasenack, Raphael Tobler, Patrick Tritschler
-
Publication number: 20200246272Abstract: A pharmaceutical carrier (20) comprises a lid part (22) and a bottom part (24), wherein at least one of the lid part (22) and the bottom part (24) has a first wall section (26, 30) with a thickness of 180-250 ?m, preferably 185-225 ?m, even more preferably 190-220 ?m, and most preferably about 215 ?m, and a second wall section (28, 32) with a thickness of 350-450 ?m, preferably 375-425 ?m, more preferably 390-410 ?m, and most preferably about 400 ?m. The first wall section (26) of the lid part (22) defines an entire top portion of the lid part (22). Alternatively or additionally thereto, the first wall section (30) of the bottom part (24) defines an entire bottom portion of the bottom part (24).Type: ApplicationFiled: September 28, 2018Publication date: August 6, 2020Inventors: Florian Beck, Hans de Waard, Sarah Gold, Stefan Hirsch, David Hook, Nikhil Kavimandan, Markus Krumme, Steffen Lang, Detlef Moll, Siddharthya Mujumdar, Anh-Thu Nguyen-Trung, Joerg Ogorka, Norbert Rasenack, Raphael Tobler, Patrick Tritschler
-
Publication number: 20180185286Abstract: Materials containing pharmaceutically active species in solid (e.g., crystal) form, and related methods, are provided, allowing for improved stability, solubility, bioavailability, and/or dissolution rates for pharmaceutically active species having poor aqueous solubility.Type: ApplicationFiled: March 31, 2015Publication date: July 5, 2018Applicants: NOVARTIS PHARMA AG, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Allan Stuart Myerson, Xiaochuan Yang, Marcus O'Mahony, Markus Krumme, Norbert Rasenack, Leia Dwyer
-
Patent number: 9156835Abstract: The invention relates to a method for producing a micronized, virtually anhydrous form of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide, said form per se, and the use thereof for producing a medicament, especially a medicament having an anticholinergic effect.Type: GrantFiled: December 7, 2006Date of Patent: October 13, 2015Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Norbert Rasenack, Michael Walz, Michael Trunk, Hagen Graebner
-
Publication number: 20100266696Abstract: A process of preparing a particulate and substantially crystalline drug substance. The process involves suspending a substantially crystalline drug substance in an anti-solvent to give a suspension, homogenising the suspension at elevated pressure to give drug particles that have a mean particle size of less than about 10 ?m, and drying the drug particles to remove any residual anti-solvent.Type: ApplicationFiled: December 11, 2008Publication date: October 21, 2010Inventors: Gerhard Muhrer, Thomas Kieckbusch, Ranjit Thakur, Norbert Rasenack, Dilraj Singh, Kurt Schaffluetzel
-
Publication number: 20100247658Abstract: A process for reducing the tendency of a drug substance to aggregate and/or agglomerate during storage. The process involves micronising the drug substance to give a mean particle size of less than about 10 ?m, and exposing the micronised drug substance to a dry environment at an elevated temperature between 40° C. and 120° C. for at least six hours.Type: ApplicationFiled: December 11, 2008Publication date: September 30, 2010Inventors: Gerhard Muhrer, Norbert Rasenack, Michael Juhnke
-
Publication number: 20100215590Abstract: The invention relates to a method for producing a micronized, virtually anhydrous form of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide, said form per se, and the use thereof for producing a medicament, especially a medicament having an anticholinergic effect.Type: ApplicationFiled: December 7, 2006Publication date: August 26, 2010Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Norbert Rasenack, Mihael Walz, Michael Trunk, Hagen Graebner
-
Publication number: 20100210681Abstract: The present invention relates to an aqueous pharmaceutical composition comprising 1-(2-dimethylaminoethyl)-3-((2R,4aS,5R,10bS)-5-phenyl-9-trifluoromethyl-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-ylmethyl)urea as active compound, to a liquid pharmaceutical composition which is suitable for the preparation of the aqueous pharmaceutical composition, and to a process for the preparation of the compositions.Type: ApplicationFiled: April 24, 2008Publication date: August 19, 2010Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNGInventors: Holger Bauer, Norbert Rasenack, Kerstin Ammer, Bianka Kemmerer, Kirstin Heil
-
Publication number: 20050139144Abstract: The invention relates to a method for producing microparticles and/or nanoparticles of a substance, wherein particles are formed from molecularly distributed substances which simultaneously stabilized in suspension. The substance is dissolved in a solvent system and subsequently a non-solvent for said substance is added whereby said non-solvent can be mixed with the solvent system for this substance. One or several crystal growth inhibitors are added and a rapid merging of solvents and non-solvents take place. The substance is precipitated by forming a dispersion of particles whose size lies in the micrometer or nanometer range.Type: ApplicationFiled: March 21, 2003Publication date: June 30, 2005Inventors: Bernd Muller, Norbert Rasenack
-
Publication number: 20050003000Abstract: The present invention relates to a process for the formation of profen crystals, which comprises carrying out the formation of solids by displacement precipitation, cooling crystallization, evaporative crystallization or a combination thereof in the presence of one or more additives, and the use of the profens thus prepared for pharmaceutical formulations.Type: ApplicationFiled: October 25, 2002Publication date: January 6, 2005Inventors: Heinz Einig, Bernd Muller, Norbert Rasenack, Katrin Friese, Dirk Franke